Isavuconazole
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Isavuconazole: From Invasive Fungal Infection (Azole Antifungal) to Migraine Disorder
One-Sentence Summary
Isavuconazole is an azole antifungal that is marketed in Singapore in oral and intravenous forms. The TxGNN model predicts it may be effective for migraine disorder with a very high score, but no clinical trials and no publications currently support this prediction. It is a model-only signal with no mechanistic rationale.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license records compiled for this report (isavuconazole is an azole antifungal) |
| Predicted New Indication | Migraine disorder |
| TxGNN Prediction Score | 98.99% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled record. Isavuconazole is an azole antifungal that inhibits fungal CYP51 (lanosterol 14-alpha-demethylase), and this is the basis of its antifungal activity.
No known pathway connects this mechanism to migraine pathophysiology (CGRP signalling, serotonergic pathways or cortical spreading depression). The high TxGNN score is therefore best read as a model-derived association, not a biologically grounded hypothesis.
The other top predictions show the same pattern. Migraine with brainstem aura and migraine susceptibility are closely related to the parent migraine node, which likely inflates their scores. Pulmonary hypertension, kyphoscoliotic heart disease, rheumatoid arthritis, Prinzmetal angina, and several rare skin disorders and nephrogenic syndrome of inappropriate antidiuresis have no plausible link either. All ten top predictions are at evidence level L4–L5 and carry a Hold recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for migraine disorder.
For the rank 6 prediction (rheumatoid arthritis), one case report was retrieved:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 37597857 | 2023 | Case report | BMJ Case Reports | Disseminated histoplasmosis in a patient on methotrexate and infliximab for rheumatoid arthritis was successfully treated with isavuconazole. This supports antifungal use in an immunosuppressed host, not efficacy against rheumatoid arthritis. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15716P | CRESEMBA CAPSULES 100MG | Capsule | Not stated in the compiled record |
| SIN15717P | CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG | Injection, powder, lyophilised, for solution | Not stated in the compiled record |
Both licenses are valid single-ingredient products. An oral route (capsule) and an injectable route (infusion) are available.
Safety Considerations
Please refer to the package insert for safety information.
Points from the compiled rationale that are relevant if repurposing were ever explored:
- As an azole, isavuconazole inhibits CYP3A4, which could change exposure to co-administered drugs (for example, pulmonary arterial hypertension medicines).
- Isavuconazole is associated with QT shortening, which is a consideration in patients with cardiac conditions.
No drug interaction records were found in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The migraine prediction rests on a model score alone. There are no clinical trials or publications, and no plausible mechanistic link between CYP51 inhibition and migraine biology. Safety information from the package insert has also not been reviewed.
To proceed, the following is needed:
- Obtain and review the Singapore package insert (warnings, contraindications, approved indications)
- Obtain detailed mechanism of action data from DrugBank
- Establish a credible biological hypothesis linking isavuconazole to migraine, supported by preclinical or mechanistic studies
- Assess route compatibility and drug interaction risk for the target population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.